⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504144 | 0.82 | — | — | |
| SCHEMBL4500975 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL8909834 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL2737210 | 0.78 | CA12 (0.44) | — | |
| SCHEMBL147479 | 0.77 | — | — | |
| SCHEMBL20272748 | 0.75 | — | — | |
| SCHEMBL7927939 | 0.75 | — | — | |
| SCHEMBL7967923 | 0.73 | — | — | |
| SCHEMBL5715676 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL24424824 | 0.71 | CA12 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223756-B2 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | claimed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | claimed |
| US-7141577-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | claimed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | claimed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | claimed |
| US-20050009850-A1 | Quinazoline compounds with therapeutic use | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | claimed |
| EP-1451180-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |